StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Puma Biotechnology's price to sales ratio was 1.8× on Nov 11, 2026, against 1.2× a year earlier. Over the last 5 years it ranged from 0.4× to 2.3×, with a median of 0.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.8×+0.4
2025Dec 31, 20251.4×+0.8
2024Dec 31, 20240.6×−0.3
2023Dec 29, 20230.9×+0.0
2022Dec 30, 20220.9×+0.4
2021Dec 31, 20210.5×−1.2
2020Dec 31, 20201.7×+0.5
2019Dec 31, 20191.2×−2.6
2018Dec 31, 20183.9×–

More Puma Biotechnology figures

See a number that looks wrong?